- Conditions
- Tumors, Hyperuricemia, Tumor Lysis Syndrome
- Interventions
- Rasburicase (SR29142)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Not listed
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 7
- States / cities
- Berkley, California • Denver, Colorado • Jacksonville, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 458
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neuroblastoma, Ganglioneuroblastoma
- Interventions
- Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 18 Months to 26 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2038
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Blunt Abdominal Trauma
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 3 Years to 60 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Perianal Fistula Due to Crohn's Disease (Disorder)
- Interventions
- Mesenchymal stem cells
- Drug
- Lead sponsor
- Anthony Lembo
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL
- Interventions
- CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine, Mesna, CliniMACS, Leukapheresis
- Biological · Drug · Device + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Ulcerative Colitis
- Interventions
- RAVANS, RAVANS-sham
- Device
- Lead sponsor
- Cala Health, Inc.
- Industry
- Eligibility
- 10 Years to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Pediatric Cancer, Survivorship
- Interventions
- Sexual Function Screening Approach
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado
- Conditions
- Glycogen Storage Disease Type IB
- Interventions
- Specimen Donation
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 4 Years to 85 Years
- Enrollment
- 6 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- ChromoSeq® assay testing
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Weeks and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Akron, Ohio • Salt Lake City, Utah
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Pediatric Solid Tumor
- Interventions
- Genetic testing and GAIN report
- Genetic
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 12
- States / cities
- San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
- Interventions
- CLR 131
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 6
- States / cities
- Palo Alto, California • New York, New York • Chapel Hill, North Carolina + 3 more
- Conditions
- Medulloblastoma, Rhabdomyosarcoma, Neuroblastoma, Hepatoblastoma, Glioma, Astrocytoma
- Interventions
- LDE225
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Interventions
- Ribociclib, Everolimus, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 12 Months to 39 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Conductive Hearing Loss
- Interventions
- flexible conductive hearing aid
- Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 6 Months to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Angelman Syndrome
- Interventions
- rugonersen, Sham procedure
- Drug · Procedure
- Lead sponsor
- OHB Pediatrics Ltd.
- Industry
- Eligibility
- 1 Year to 50 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- San Diego, California • Chicago, Illinois • Chapel Hill, North Carolina
- Conditions
- Neuromuscular Diseases
- Interventions
- ActivPal
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia, Lymphoma
- Interventions
- SCRI-CAR22v2
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2040
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Houston, Texas + 1 more
- Conditions
- Sarcoma
- Interventions
- exatecan mesylate
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Jacksonville, Florida • New Brunswick, New Jersey + 4 more
- Conditions
- Hemorrhage
- Interventions
- TachoSil®, Surgicel® Original
- Biological · Device
- Lead sponsor
- Takeda
- Industry
- Eligibility
- Not listed
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more
- Conditions
- Crohn's Disease
- Interventions
- autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG, Melphalan, Thiotepa, Rituximab, Cyclophosphamide, G-CSF, Mesna
- Biological · Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Lymphocyte Predominant Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Interventions
- ifosfamide, bortezomib, vinorelbine tartrate, filgrastim
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Central Nervous System Tumor, Pediatric, Glioma, Ependymoma, Medulloblastoma, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma
- Interventions
- HER2-specific chimeric antigen receptor (CAR) T cell
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2039
- U.S. locations
- 1
- States / cities
- Seattle, Washington